Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations
Sehhoon Park, Bhumsuk Keam, Se Hyun Kim, Ki Hwan Kim, Yu Jung Kim, Jin-Soo Kim, Tae Min Kim, Se-Hoon Lee, Dong-Wan Kim, Jong Seok Lee, Dae Seog Heo
Cancer Res Treat. 2015;47(4):630-637.   Published online 2015 Feb 16     DOI: https://doi.org/10.4143/crt.2014.244
Citations to this article as recorded by Crossref logo
A meta-analysis of the safety and effectiveness of pemetrexed compared with gefitinib for pre-treated advanced or metastatic NSCLC
Xiaoxin Lu, Shengshu Li, Weizong Chen, Dongyang Zheng, Yuzhu Li, Fang Li
Medicine.2020; 99(29): e21170.     CrossRef
A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line
Kwai Han Yoo, Su Jin Lee, Jinhyun Cho, Ki Hyeong Lee, Keon Uk Park, Ki Hwan Kim, Eun Kyung Cho, Yoon Hee Choi, Hye Ryun Kim, Hoon-Gu Kim, Heui June Ahn, Ha Yeon Lee, Hwan Jung Yun, Jin-Hyoung Kang, Jaeheon Jeong, Moon Young Choi, Sin-Ho Jung, Jong-Mu Sun,
Cancer Research and Treatment.2019; 51(2): 718.     CrossRef
Overexpression of PTEN may increase the effect of pemetrexed on A549 cells via inhibition of the PI3K/AKT/mTOR pathway and carbohydrate metabolism
Bo Li, Junkai Zhang, Ya Su, Yiling Hou, Zhenguo Wang, Lin Zhao, Shengkai Sun, Hao Fu
Molecular Medicine Reports.2019;[Epub]     CrossRef
Treatment Patterns by EGFR Mutation Status in Non-Small Cell Lung Cancer Patients in the USA: A Retrospective Database Analysis
Kathleen M. Aguilar, Katherine B. Winfree, Catherine E. Muehlenbein, Yajun Emily Zhu, Thomas Wilson, Stewart Wetmore, Eric S. Nadler
Advances in Therapy.2018; 35(11): 1905.     CrossRef
The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors
Hyungjin Kim, Chang Min Park, Bhumsuk Keam, Sang Joon Park, Miso Kim, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo, Jin Mo Goo, Fan Yang
PLOS ONE.2017; 12(11): e0187500.     CrossRef
Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature
Caicun Zhou, Luan Di Yao
Journal of Thoracic Oncology.2016; 11(2): 174.     CrossRef
Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer
Federico Cappuzzo, Alessandro Morabito, Nicola Normanno, Paolo Bidoli, Alessandro Del Conte, Laura Giannetta, Agnese Montanino, Francesca Mazzoni, Roberta Buosi, Marco Angelo Burgio, Giulio Cerea, Rita Chiari, Diego Cortinovis, Giovanna Finocchiaro, Luisa
Lung Cancer.2016; 99: 31.     CrossRef
Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment options
Jordi Remon, Benjamin Besse
ESMO Open.2016; 1(4): e000081.     CrossRef
Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs
Su Jin Lee, Jong-Mu Sun, Se Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Lung Cancer.2015; 90(2): 261.     CrossRef